CommentDeclining breast cancer incidence and decreased HRT use
References (18)
- et al.
Global cancer statistics, 2002
CA Cancer J Clin
(2005) - et al.
Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia
Med J Aust
(2008) - et al.
Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population
J Natl Cancer Inst
(2007) - et al.
The decrease in breast-cancer incidence in 2003 in the United States
N Engl J Med
(2007) Breast cancer drop linked to fall in use of HRT. New Zealand Herald
- et al.
A decline in breast-cancer incidence
N Engl J Med
(2007) - et al.
Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy
Breast Cancer Res Treat
(2008) - et al.
Decline in breast cancer incidence in 2005 and 2006 in France: a paradoxical trend
Bull Can
(2008) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer
Lancet
(1997)
Cited by (106)
Estrogenic and anti-inflammatory effects of pseudoprotodioscin in atherosclerosis-prone mice: Insights into endothelial cells and perivascular adipose tissues
2020, European Journal of PharmacologyCitation Excerpt :However, little was known regarding to the precise pharmacological effects of saponins compounds involved. More importantly, the beneficial effect of hormone replacement therapy on the cardiovascular system of postmenopausal women has been contested for the detrimental side effects of its clinical use, which include ovarian and breast cancers (Kumle, 2008). Thus, PPD, with previously reported anti-tumor properties (Dong et al., 2001), is a promising agent which exhibits potential clinical therapeutic effects on estrogen deficiency-associated atherosclerosis, such as that in postmenopausal women.
Inducing or Preventing Subsequent Malignancies for Breast Cancer Survivors? Double-edged Sword of Estrogen Receptor and Progesterone Receptor
2018, Clinical Breast CancerCitation Excerpt :Owing to the increasing usage of mammography screening and menopausal hormones, the BC incidence rates increased significantly in the 1980s and 1990s.3,4 After 2002, with the decreased usage of menopausal hormones,5 the BC rate decreased, especially in white women and for hormone receptor-positive (HR+) BC.6,7 In the United States, the overall 5-year relative survival rate improved from 75.1% in 1975 to 1977 to 90.0% in 2001 to 2007.8
Menopausal hormone therapy and cancer risk: An overestimated risk?
2017, European Journal of CancerOsteoporosis
2015, Endocrinology: Adult and Pediatric